MedTrace Logo

Omega 3 Fatty Acids on Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride

NCT03917940 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-11-22

No results posted yet for this study

Summary

study the effect of omega 3 fatty acids on blood glucose, lipids profile, serum Irisin and sirtuin-1 in type 2 diabetic mellitus patients treated with glimepiride.

Conditions

  • Diabetic Patients

Interventions

DIETARY_SUPPLEMENT

Omega 3 fatty acids 1000 mg per day + glimepiride 2 mg or 3 mg oral

Omega 3 fatty acids 1000 mg per day oral

DRUG

Glimepiride

glimepiride 2 mg or 3 mg per day oral

Sponsors & Collaborators

  • Damanhour University

    lead OTHER

Principal Investigators

  • Maged W Helmy, Ass. Prof. · Pharmacology & Toxicology department- faculty of pharmacy- Damanhour University.

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-31
Primary Completion
2020-05-01
Completion
2020-05-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03917940 on ClinicalTrials.gov